New Releases from NCBI BookshelfDurvalumab (Imfinzi) and Tremelimumab (Imjudo): Therapeutic area: Metastatic non–small cell lung cancer (NSCLC): Reimbursement Review [Internet].Durvalumab (Imfinzi) and Tremelimumab (Imjudo): Therapeutic area: Metastatic non–small cell lung cancer (NSCLC): Reimbursement Review [Internet].

By admin / December 30, 2025

Post Content

New Releases from NCBI BookshelfDurvalumab (Imfinzi), Carboplatin, Paclitaxel: Therapeutic area: Endometrial cancer that is mismatch repair deficient (dMMR): Reimbursement Review [Internet].Durvalumab (Imfinzi), Carboplatin, Paclitaxel: Therapeutic area: Endometrial cancer that is mismatch repair deficient (dMMR): Reimbursement Review [Internet].

New Releases from NCBI BookshelfBelantamab mafodotin (Blenrep), bortezomib, dexamethasone: Indication: Belantamab mafodotin is indicated in combination with bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy: Reimbursement Recommendation [Internet].Belantamab mafodotin (Blenrep), bortezomib, dexamethasone: Indication: Belantamab mafodotin is indicated in combination with bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy: Reimbursement Recommendation [Internet].

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

Registration No: 771800548 Contact Number : +91-8249516996

Publication
Skill Development
Blog Writing

Research
Awareness Camp
Digital Research

Ngo Darpan
Service
Donation

Term and Condition
Privacy Policy
Disclaimer

Scroll to Top

Leave a Comment Cancel Reply

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.